235 related articles for article (PubMed ID: 21787290)
1. The role of BMPs in bone anabolism and their potential targets SOST and DKK1.
Kamiya N
Curr Mol Pharmacol; 2012 Jun; 5(2):153-63. PubMed ID: 21787290
[TBL] [Abstract][Full Text] [Related]
2. Loss-of-function of ACVR1 in osteoblasts increases bone mass and activates canonical Wnt signaling through suppression of Wnt inhibitors SOST and DKK1.
Kamiya N; Kaartinen VM; Mishina Y
Biochem Biophys Res Commun; 2011 Oct; 414(2):326-30. PubMed ID: 21945937
[TBL] [Abstract][Full Text] [Related]
3. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts.
Kamiya N; Kobayashi T; Mochida Y; Yu PB; Yamauchi M; Kronenberg HM; Mishina Y
J Bone Miner Res; 2010 Feb; 25(2):200-10. PubMed ID: 19874086
[TBL] [Abstract][Full Text] [Related]
4. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway.
Kamiya N; Ye L; Kobayashi T; Mochida Y; Yamauchi M; Kronenberg HM; Feng JQ; Mishina Y
Development; 2008 Nov; 135(22):3801-11. PubMed ID: 18927151
[TBL] [Abstract][Full Text] [Related]
5. Estrogen Modulates Bone Morphogenetic Protein-Induced Sclerostin Expression Through the Wnt Signaling Pathway.
Kim RY; Yang HJ; Song YM; Kim IS; Hwang SJ
Tissue Eng Part A; 2015 Jul; 21(13-14):2076-88. PubMed ID: 25837159
[TBL] [Abstract][Full Text] [Related]
6. Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development.
Okamoto M; Murai J; Yoshikawa H; Tsumaki N
J Bone Miner Res; 2006 Jul; 21(7):1022-33. PubMed ID: 16813523
[TBL] [Abstract][Full Text] [Related]
7. New insights on the roles of BMP signaling in bone-A review of recent mouse genetic studies.
Kamiya N; Mishina Y
Biofactors; 2011; 37(2):75-82. PubMed ID: 21488130
[TBL] [Abstract][Full Text] [Related]
8. Co-expression of BMPs and BMP-inhibitors in human fractures and non-unions.
Kloen P; Lauzier D; Hamdy RC
Bone; 2012 Jul; 51(1):59-68. PubMed ID: 22521262
[TBL] [Abstract][Full Text] [Related]
9. High-concentration of BMP2 reduces cell proliferation and increases apoptosis via DKK1 and SOST in human primary periosteal cells.
Kim HK; Oxendine I; Kamiya N
Bone; 2013 May; 54(1):141-50. PubMed ID: 23360788
[TBL] [Abstract][Full Text] [Related]
10. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
[TBL] [Abstract][Full Text] [Related]
11. The Deletion of Hdac4 in Mouse Osteoblasts Influences Both Catabolic and Anabolic Effects in Bone.
Nakatani T; Chen T; Johnson J; Westendorf JJ; Partridge NC
J Bone Miner Res; 2018 Jul; 33(7):1362-1375. PubMed ID: 29544022
[TBL] [Abstract][Full Text] [Related]
12. OPG and RANKL mRNA and protein expressions in the primary and secondary metaphyseal trabecular bone of PTH-treated rats are independent of that of SOST.
Silvestrini G; Ballanti P; Sebastiani M; Leopizzi M; Di Vito M; Bonucci E
J Mol Histol; 2008 Apr; 39(2):237-42. PubMed ID: 18158586
[TBL] [Abstract][Full Text] [Related]
13. Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass.
Kamiya N; Ye L; Kobayashi T; Lucas DJ; Mochida Y; Yamauchi M; Kronenberg HM; Feng JQ; Mishina Y
J Bone Miner Res; 2008 Dec; 23(12):2007-17. PubMed ID: 18684091
[TBL] [Abstract][Full Text] [Related]
14. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF.
Fujita K; Janz S
Mol Cancer; 2007 Oct; 6():71. PubMed ID: 17971207
[TBL] [Abstract][Full Text] [Related]
15. Distinct Gene Expression Patterns Defining Human Osteoblasts' Response to BMP2 Treatment: Is the Therapeutic Success All a Matter of Timing?
Ehnert S; Aspera-Werz RH; Freude T; Reumann MK; Ochs BG; Bahrs C; Schröter S; Wintermeyer E; Nussler AK; Pscherer S
Eur Surg Res; 2016; 57(3-4):197-210. PubMed ID: 27441597
[TBL] [Abstract][Full Text] [Related]
16. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
[TBL] [Abstract][Full Text] [Related]
17. Insulin-dependent diabetes mellitus decreases osteoblastogenesis associated with the inhibition of Wnt signaling through increased expression of Sost and Dkk1 and inhibition of Akt activation.
Hie M; Iitsuka N; Otsuka T; Tsukamoto I
Int J Mol Med; 2011 Sep; 28(3):455-62. PubMed ID: 21567076
[TBL] [Abstract][Full Text] [Related]
18. Controversy of physiological vs. pharmacological effects of BMP signaling: Constitutive activation of BMP type IA receptor-dependent signaling in osteoblast lineage enhances bone formation and resorption, not affecting net bone mass.
Kamiya N; Atsawasuwan P; Joiner DM; Waldorff EI; Goldstein S; Yamauchi M; Mishina Y
Bone; 2020 Sep; 138():115513. PubMed ID: 32603910
[TBL] [Abstract][Full Text] [Related]
19. Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes.
Rhee Y; Lee EY; Lezcano V; Ronda AC; Condon KW; Allen MR; Plotkin LI; Bellido T
J Biol Chem; 2013 Oct; 288(41):29809-20. PubMed ID: 23963454
[TBL] [Abstract][Full Text] [Related]
20. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity.
Kusu N; Laurikkala J; Imanishi M; Usui H; Konishi M; Miyake A; Thesleff I; Itoh N
J Biol Chem; 2003 Jun; 278(26):24113-7. PubMed ID: 12702725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
